感染性休克的代谢亚表型及其时间稳定性与临床结局的关联
在 LeoPARDS(470 例患者、1402 份样本)和 VANISH(173 例患者、493 份样本)两项双盲随机试验中,对感染性休克患者起病后多个时间点的血清进行代谢组学分析,用 k-means 聚类在 LeoPARDS 中识别代谢簇,并用弹性网分类器在 VANISH 中预测。共发现三种亚型,主要决定因素为脂质尤其是溶血磷脂;低溶血磷脂亚型与更高的循环细胞因子水平相关。低溶血磷脂亚型持续存在与较高死亡率相关(LeoPARDS 簇 2 OR 3.66,95%CI 1.88–7.20,p=0.0001;簇 3 OR 2.49,95%CI 1.29–4.81,p=0.006;VANISH 簇 2 OR 4.13,95%CI 1.17–15.61,p=0.03;簇 3 OR 3.22,95%CI 1.09–9.92,p=0.04;均与簇 1 比较)。未发现任何试验干预按基线代谢亚型存在治疗效应异质性。作者认为监测这些亚型可能有助于识别不良结局风险患者并指导溶血磷脂补充等新疗法。
要点
- 在 LeoPARDS 中,持续低溶血磷脂亚型簇 2 的死亡 OR 为 3.66(95%CI 1.88–7.20,p=0.0001),簇 3 为 2.49(95%CI 1.29–4.81,p=0.006),均与簇 1 比较。
- 在 VANISH 中,持续低溶血磷脂亚型簇 2 的死亡 OR 为 4.13(95%CI 1.17–15.61,p=0.03),簇 3 为 3.22(95%CI 1.09–9.92,p=0.04),均与簇 1 比较。
- 代谢亚型的主要决定因素是脂质种类,尤其是溶血磷脂;低溶血磷脂亚型与更高的循环细胞因子水平相关。
- 未发现任何试验干预按基线代谢亚型存在治疗效应异质性。
- 作者认为监测这些亚型可能有助于识别不良结局风险患者并指导溶血磷脂补充等新疗法。
适用人群与场景
- 两项双盲随机试验(LeoPARDS 和 VANISH)中纳入的感染性休克患者,于休克起病后不久入组,并在最多四个时间点采集血清。
研究设计与关键结果
- 研究类型:对两项双盲随机试验(LeoPARDS 和 VANISH)的代谢组学分析;LeoPARDS 共 1402 份样本来自 470 例患者,VANISH 共 493 份样本来自 173 例患者。
- 方法:在 LeoPARDS 中使用 k-means 聚类从 474 种代谢物中识别代谢簇,并用弹性网分类器在 VANISH 中预测。
- 结果:发现三种亚型,主要决定因素为脂质种类,尤其是溶血磷脂;低溶血磷脂亚型与更高的循环细胞因子水平相关。
- 低溶血磷脂亚型持续存在与较高死亡率相关:LeoPARDS 簇 2 OR 3.66(95%CI 1.88–7.20),p=0.0001;簇 3 OR 2.49(95%CI 1.29–4.81),p=0.006;VANISH 簇 2 OR 4.13(95%CI 1.17–15.61),p=0.03;簇 3 OR 3.22(95%CI 1.09–9.92),p=0.04;均与簇 1 比较。
- 未发现任何试验干预按基线代谢亚型存在治疗效应异质性。
证据类型、等级与局限
- 证据类型:对两项双盲随机试验(LeoPARDS 和 VANISH)的二次分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为监测这些代谢亚型可能有助于识别不良结局风险患者并指导溶血磷脂补充等新疗法。
- 原文未发现任何试验干预按基线代谢亚型存在治疗效应异质性。
指南或共识出处
- ClinicalTrials.gov 注册号:VANISH:ISRCTN 20769191;LeoPARDS:ISRCTN12776039。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
PURPOSE: Machine learning has shown promise to detect useful subgroups of patients with sepsis from gene expression and protein data. This approach has rarely been deployed in metabolomic datasets. Metabolomic data are of interest as they capture effects from the genome, proteome, and environmental. We aimed to discover metabolic sub-phenotypes of septic shock, examine their temporal stability and association with clinical outcome.
METHODS: Analysis was performed in two double-blind randomized trials in septic shock (LeoPARDS (1402 samples from 470 patients) and VANISH (493 samples from 173 patients)). Patients were included soon after the onset of shock and had serum collected at up to four time points. Metabolic clusters were identified from 474 metabolites using k-means clustering in LeoPARDS and predicted in VANISH with an elastic net classifier.
RESULTS: Three sub-phenotypes were found. The main determinants of cluster membership were lipid species, especially lysophospholipids. Low lysophospholipid sub-phenotypes were associated with higher circulating cytokine levels. Persistence of low lysophospholipid sub-phenotypes was associated with higher mortality compared to the high lysophospholipid sub-phenotype (LeoPARDS: cluster 2 odds ratio 3.66 (95% CI 1.88-7.20), p = 0.0001, cluster 3 2.49 (1.29-4.81), p = 0.006; VANISH: cluster 2 4.13 (1.17-15.61), p = 0.03), cluster 3 3.22 (1.09-9.92), p = 0.04, vs cluster 1). We found no heterogeneity of treatment effect for any of the trial interventions by baseline metabolic sub-phenotype.
CONCLUSION: Three metabolic subgroups exist in septic shock which evolve over time. Persistence of low lysophospholipid sub-phenotypes is associated with mortality. Monitoring these subgroups could help identify patients at risk of poor outcome and direct novel therapies such as lysophospholipid supplementation.
REGISTRATION: Clinicaltirals.gov Identifiers, VANISH: ISRCTN 20769191, LeoPARDS: ISRCTN12776039.
参考来源
- Antcliffe DB, Harte E, Hussain H, et al. Metabolic septic shock sub-phenotypes, stability over time and association with clinical outcome. Intensive Care Med. 2025. PMID: 40163132. doi:10.1007/s00134-025-07859-4
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。